Literature DB >> 22848311

Different expression of alternative lengthening of telomere (ALT)-associated proteins/mRNAs in osteosarcoma cell lines.

Yi Zhang1, Lin Cai, Ren-Xiong Wei, Hao Hu, Wei Jin, Xiao-Bin Zhu.   

Abstract

Tumors, including osteosarcoma (OS), are capable of evading senescence and cell death, which is caused by telomere loss with cell division. Alternative lengthening of telomeres (ALT) is considered as the main telomere maintenance mechanism in OS. In this study, we investigated the expression of ALT-associated proteins and mRNAs in human OS cell lines. Western blotting was used to detect the protein expression in OS cell lines, while the expression of mRNA was determined by reverse-transcriptase PCR and quantitative real-time PCR analysis. Whole-genome expression arrays were used to analyze the expression of all the mRNAs involved in telomere maintenance mechanisms (TMMs) including human telomerase reverse transcriptase, promyelocytic leukemia proteins and other related proteins. OS and normal cell lines do not express telomerase reverse transcriptase (hTERT) as a key subunit of telomerase, although they show varying levels of ALT-associated proteins and mRNAs such as PML, Rad52, MRE11 and FEN1 by Western blotting and quantitative real-time PCR analysis. A number of mRNAs that play essential roles in ALT are expressed more in OS cell lines than in the osteoblast cell line, as shown by whole-genome expression arrays. In conclusion, OS cell lines maintain their telomere length primarily through the ALT mechanism. There are numerous other proteins that regulate this process in OS; therefore, anti-ALT therapy may be a more effective method to treat OS than anti-telomerase therapy.

Entities:  

Year:  2011        PMID: 22848311      PMCID: PMC3406509          DOI: 10.3892/ol.2011.403

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  45 in total

1.  Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.

Authors:  K Perrem; L M Colgin; A A Neumann; T R Yeager; R R Reddel
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Telomerase-associated protein TEP1 is not essential for telomerase activity or telomere length maintenance in vivo.

Authors:  Y Liu; B E Snow; M P Hande; G Baerlocher; V A Kickhoefer; D Yeung; A Wakeham; A Itie; D P Siderovski; P M Lansdorp; M O Robinson; L Harrington
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

3.  Functional characterization and developmental regulation of mouse telomerase RNA.

Authors:  M A Blasco; W Funk; B Villeponteau; C W Greider
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

4.  Vaults and telomerase share a common subunit, TEP1.

Authors:  V A Kickhoefer; A G Stephen; L Harrington; M O Robinson; L H Rome
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

5.  Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression.

Authors:  Aurora Costa; Maria Grazia Daidone; Laura Daprai; Raffaella Villa; Sabrina Cantù; Silvana Pilotti; Luigi Mariani; Alessandro Gronchi; Jeremy D Henson; Roger R Reddel; Nadia Zaffaroni
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

Review 6.  Alternative lengthening of telomeres in mammalian cells.

Authors:  Jeremy D Henson; Axel A Neumann; Thomas R Yeager; Roger R Reddel
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

7.  Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas.

Authors:  J Nakayama; H Tahara; E Tahara; M Saito; K Ito; H Nakamura; T Nakanishi; E Tahara; T Ide; F Ishikawa
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

8.  A role for PML3 in centrosome duplication and genome stability.

Authors:  Zhi-Xiang Xu; Wen-Xin Zou; Pei Lin; Kun-Sang Chang
Journal:  Mol Cell       Date:  2005-03-04       Impact factor: 17.970

9.  Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.

Authors:  L Endo-Munoz; A Cumming; S Sommerville; I Dickinson; N A Saunders
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

10.  In vivo roles of Rad52, Rad54, and Rad55 proteins in Rad51-mediated recombination.

Authors:  Neal Sugawara; Xuan Wang; James E Haber
Journal:  Mol Cell       Date:  2003-07       Impact factor: 17.970

View more
  9 in total

1.  Alternative lengthening of telomeres: recurrent cytogenetic aberrations and chromosome stability under extreme telomere dysfunction.

Authors:  Despoina Sakellariou; Maria Chiourea; Christina Raftopoulou; Sarantis Gagos
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

2.  The roles of telomerase in the generation of polyploidy during neoplastic cell growth.

Authors:  Agni Christodoulidou; Christina Raftopoulou; Maria Chiourea; George K Papaioannou; Hirotoshi Hoshiyama; Woodring E Wright; Jerry W Shay; Sarantis Gagos
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

Review 3.  Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.

Authors:  Pooja Hingorani; Katherine Janeway; Brian D Crompton; Cigall Kadoch; Crystal L Mackall; Javed Khan; Jack F Shern; Joshua Schiffman; Lisa Mirabello; Sharon A Savage; Marc Ladanyi; Paul Meltzer; Carol J Bult; Peter C Adamson; Philip J Lupo; Rajen Mody; Steven G DuBois; D Williams Parsons; Chand Khanna; Ching Lau; Douglas S Hawkins; R Lor Randall; Malcolm Smith; Poul H Sorensen; Sharon E Plon; Stephen X Skapek; Stephen Lessnick; Richard Gorlick; Damon R Reed
Journal:  Cancer Genet       Date:  2016-04-05

Review 4.  Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?

Authors:  Luca Pompili; Carlo Leonetti; Annamaria Biroccio; Erica Salvati
Journal:  J Exp Clin Cancer Res       Date:  2017-12-22

5.  Heat treatment dependent cytotoxicity of silicalite-1 films deposited on Ti-6Al-4V alloy evaluated by bone-derived cells.

Authors:  Ivana Nemcakova; Ivan Jirka; Martina Doubkova; Lucie Bacakova
Journal:  Sci Rep       Date:  2020-06-11       Impact factor: 4.379

6.  Identification of a Two-Gene (PML-EPB41) Signature With Independent Prognostic Value in Osteosarcoma.

Authors:  Shengye Liu; Jiamei Liu; Xuechen Yu; Tao Shen; Qin Fu
Journal:  Front Oncol       Date:  2020-01-24       Impact factor: 6.244

7.  Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors.

Authors:  Tomas Goncalves; Georgia Zoumpoulidou; Carlos Alvarez-Mendoza; Caterina Mancusi; Laura C Collopy; Sandra J Strauss; Sibylle Mittnacht; Kazunori Tomita
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-07

8.  RNA 5-methylcytosine status is associated with DNMT2/TRDMT1 nuclear localization in osteosarcoma cell lines.

Authors:  Gabriela Betlej; Tomasz Ząbek; Anna Lewińska; Dominika Błoniarz; Iwona Rzeszutek; Maciej Wnuk
Journal:  J Bone Oncol       Date:  2022-07-30       Impact factor: 4.491

9.  Identification and Validation of a Potent Multi-miRNA Signature for Prediction of Prognosis of Osteosarcoma Patients.

Authors:  Xinle Luo; Jiuyang Tang; Huabing Xuan; Jianlin Liu; Xi Li
Journal:  Med Sci Monit       Date:  2020-02-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.